Subscribe to RSS
DOI: 10.1055/s-0037-1603795
Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Review
Publication History
07 February 2017
08 May 2017
Publication Date:
23 June 2017 (online)
Abstract
Platelet-rich plasma (PRP) consists of a volume of plasma with a platelet concentration above whole blood baseline values. Based on the group of bioactive molecules that platelets release when activated and the regenerative and healing potential they have, the use of PRP has followed a rapid development and application in orthopedics, with applications that frequently outpaces the basic science and clinical evidence supporting its use. Currently, significant heterogeneity and discrepancies exist between the different types of available PRP formulations. Because of this, although there is a vast literature on PRP, the published results are often contradictory, making it challenging to obtain definitive conclusions. Therefore, the purpose of this review article is to provide an overview of PRP with a focus on (1) preparation protocols; (2) nomenclature and classifications; (3) biological effects; and (4) clinical evidence of its role in the treatment of knee osteoarthritis. On the basis of the current evidence, although PRP injections reduced pain and improved function more efficiently when compared with controls, these findings need to be interpreted with caution due to the limited level of evidence and high risk of bias. There is a need for a standardized scientific approach for analyzing PRP formulations composition, beginning with standardization of PRP preparation protocols, and detailed characterization of the final product (e.g., platelets and leukocytes content, volume, growth factors profile). Good quality and sizeable double-blinded randomized trials will be required to establish whether or not PRP injections are effective and should be included as a standard of care for the management of patients with knee osteoarthritis.
-
References
- 1 Sim X, Poncz M, Gadue P, French DL. Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets. Blood 2016; 127 (10) 1227-1233
- 2 Parry MF, Jacobs B, Scully B, Neu HC. Thrombocytosis: an acute-phase reactant, not an adverse reaction to the new beta-lactam antibiotics. Diagn Microbiol Infect Dis 1984; 2 (03) 229-231
- 3 Qiu Y, Ciciliano J, Myers DR, Tran R, Lam WA. Platelets and physics: How platelets “feel” and respond to their mechanical microenvironment. Blood Rev 2015; 29 (06) 377-386
- 4 Amable PR, Carias RB, Teixeira MV. , et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther 2013; 4 (03) 67
- 5 Hardwick J. Blood processing. ISBT Sci Ser 2008; 3 (02) 148-176
- 6 Kon E, Filardo G, Di Martino A, Marcacci M. Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use. Knee Surg Sports Traumatol Arthrosc 2011; 19 (04) 516-527
- 7 Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev 2015; 29 (03) 153-162
- 8 Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009; 23 (04) 177-189
- 9 Bryan D, Parvizi J, Austin M. , et al; Workgroup of the American Association of Hip and Knee Surgeons Evidence Based Committee. Obesity and total joint arthroplasty: a literature based review. J Arthroplasty 2013; 28 (05) 714-721
- 10 Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006; 20 (01) 3-25
- 11 Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 2013; 9 (12) 721-730
- 12 Filardo G, Kon E, Di Martino A. , et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord 2012; 13 (01) 229
- 13 Jang SJ, Kim JD, Cha SS. Platelet-rich plasma (PRP) injections as an effective treatment for early osteoarthritis. Eur J Orthop Surg Traumatol 2013; 23 (05) 573-580
- 14 Kon E, Buda R, Filardo G. , et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2010; 18 (04) 472-479
- 15 Metcalf KB, Mandelbaum BR, McIlwraith CW. Application of platelet-rich plasma to disorders of the knee joint. Cartilage 2013; 4 (04) 295-312
- 16 Pourcho AM, Smith J, Wisniewski SJ, Sellon JL. Intraarticular platelet-rich plasma injection in the treatment of knee osteoarthritis: review and recommendations. Am J Phys Med Rehabil 2014; 93 (11) (Suppl. 03) S108-S121
- 17 Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. J Cutan Aesthet Surg 2014; 7 (04) 189-197
- 18 Basu D, Kulkarni R. Overview of blood components and their preparation. Indian J Anaesth 2014; 58 (05) 529-537
- 19 Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009; 27 (03) 158-167
- 20 Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang C-Q, Pinto NR, Bielecki T. Classification of platelet concentrates (platelet-rich plasma-PRP, platelet-rich fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J 2014; 4 (01) 3-9
- 21 Dohan DM, Choukroun J, Diss A. , et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101 (03) e37-e44
- 22 Dohan DM, Choukroun J, Diss A. , et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101 (03) e45-e50
- 23 Choukroun J, Diss A, Simonpieri A. , et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101 (03) e56-e60
- 24 Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol 2012; 13 (07) 1185-1195
- 25 DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthroscopy 2012; 28 (07) 998-1009
- 26 Marlovits S, Mousavi M, Gäbler C, Erdös J, Vécsei V. A new simplified technique for producing platelet-rich plasma: a short technical note. Eur Spine J 2004; 13 (Suppl. 01) S102-S106
- 27 Halpern BC, Chaudhury S, Rodeo SA. The role of platelet-rich plasma in inducing musculoskeletal tissue healing. HSS J 2012; 8 (02) 137-145
- 28 Park YG, Han SB, Song SJ, Kim TJ, Ha CW. Platelet-rich plasma therapy for knee joint problems: review of the literature, current practice and legal perspectives in Korea. Knee Surg Relat Res 2012; 24 (02) 70-78
- 29 Hall MP, Band PA, Meislin RJ, Jazrawi LM, Cardone DA. Platelet-rich plasma: current concepts and application in sports medicine. J Am Acad Orthop Surg 2009; 17 (10) 602-608
- 30 Zhu Y, Yuan M, Meng HY. , et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review. Osteoarthritis Cartilage 2013; 21 (11) 1627-1637
- 31 Roh YH, Kim W, Park KU, Oh JH. Cytokine-release kinetics of platelet-rich plasma according to various activation protocols. Bone Joint Res 2016; 5 (02) 37-45
- 32 Gay CG, Winkles JA. The half-lives of platelet-derived growth factor A- and B-chain mRNAs are similar in endothelial cells and unaffected by heparin-binding growth factor-1 or cycloheximide. J Cell Physiol 1991; 147 (01) 121-127
- 33 Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone 2004; 34 (04) 665-671
- 34 Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 2011; 39 (10) 2135-2140
- 35 McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am 2012; 94 (19) e143 , 1–8
- 36 van Buul GM, Koevoet WLM, Kops N. , et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 2011; 39 (11) 2362-2370
- 37 Qin J, Theis KA, Barbour KE, Helmick CG, Baker NA, Brady TJ. ; Centers for Disease Control and Prevention (CDC). Impact of arthritis and multiple chronic conditions on selected life domains-United States, 2013. MMWR Morb Mortal Wkly Rep 2015; 64 (21) 578-582
- 38 Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009; 15 (8, Suppl): S230-S235
- 39 Campbell KA, Saltzman BM, Mascarenhas R. , et al. Does intra-articular platelet-rich plasma injection provide clinically superior outcomes compared with other therapies in the treatment of knee osteoarthritis? A systematic review of overlapping meta-analyses. Arthroscopy 2015; 31 (11) 2213-2221
- 40 Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy 2016; 32 (03) 495-505
- 41 Laudy ABM, Bakker EWP, Rekers M, Moen MH. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med 2015; 49 (10) 657-672
- 42 Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ. Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med 2016; 44 (03) 792-800
- 43 Sadabad HN, Behzadifar M, Aresteh F, Behzadifar M, Dehghan HR. Efficacy of platelet-rich plasma versus hyaluronic acid for treatment of knee osteoarthritis: A systematic review and meta-analysis. Electron Physician 2016; 8 (03) 2115-2122
- 44 Lai LP, Stitik TP, Foye PM, Georgy JS, Patibanda V, Chen B. Use of platelet-rich plasma in intra-articular knee injections for osteoarthritis: a systematic review. PM R 2015; 7 (06) 637-648
- 45 Anitua E, Sánchez M, Aguirre JJ, Prado R, Padilla S, Orive G. Efficacy and safety of plasma rich in growth factors intra-articular infiltrations in the treatment of knee osteoarthritis. Arthroscopy 2014; 30 (08) 1006-1017
- 46 Cerza F, Carnì S, Carcangiu A. , et al. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med 2012; 40 (12) 2822-2827
- 47 Vaquerizo V, Plasencia MÁ, Arribas I. , et al. Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial. Arthroscopy 2013; 29 (10) 1635-1643
- 48 Khoshbin A, Leroux T, Wasserstein D. , et al. The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synthesis. Arthroscopy 2013; 29 (12) 2037-2048
- 49 Chang KV, Hung CY, Aliwarga F, Wang TG, Han DS, Chen WS. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. Arch Phys Med Rehabil 2014; 95 (03) 562-575
- 50 Sheth U, Simunovic N, Klein G. , et al. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J Bone Joint Surg Am 2012; 94 (04) 298-307